Skip to main content
. Author manuscript; available in PMC: 2024 Nov 1.
Published in final edited form as: Blood Rev. 2022 Nov 13;62:101034. doi: 10.1016/j.blre.2022.101034

Table 1.

History of Preclinical Studies on Cyclophosphamide-Induced Tolerance

Cy prolongs allogeneic skin graft survival in mice Reference 8
Cy most effective agent in preventing Ab production in mice Reference 5
Confirmation that Cy can prevent Ab production in mice Reference 6
Cy prolongs allogeneic skin graft survival in rats Reference 7
PTCy limits GVHD in mice Reference 13
PTCy limits GVHD in mice, but is most effective at high doses Reference 18
Confirmation that PTCy can limit GVHD in mice Reference 20
Both allogeneic antigens and stem cells are needed for Cy-induced skin allograft tolerance in mice Reference 10
Cy prolongs survival of allogeneic heart grafts in mice Reference 11
CsA interferes with allogeneic skin graft survival in mice Reference 12
PTCy allows haplo BMT after nonmyeloablative conditioning in mice Reference 25

Cy – cyclophosphamide, PTCy – post-transplant cyclophosphamide, Ab – antibody, GVHD – graft-vs-host disease, CsA – cyclosporine, haplo – haploidentical, BMT – blood or marrow transplantation